Association of Anticholinergic Burden With Onset of Delirium in Older Adults With Alzheimer Dementia:

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

450 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-01-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Drugs with anticholinergic properties are commonly prescribed to older persons despite growing evidence of their significant adverse effects. However, limited data are available concerning their contribution to time of onset of delirium. This study aimed to determine the potential association of higher anticholinergic burden to early-onset of delirium superimposed dementia in the older adult.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Anticholinergic Burden - Treatment Optimization

NCT03208569

Anticholinergics Cognitive Function

COMPLETED

Cholinesterase Activity and DeliriUm During Critical Illness Study

NCT03098472

Delirium Cognitive Impairment

COMPLETED

Quetiapine in Prevention of Delirium

NCT05793632

Delirium

COMPLETED PHASE2

Delirium Related to Proton Pump Inhibitors Use

NCT05815550

Proton Pump Inhibitor Adverse Reaction Delirium Hyponatremia

COMPLETED

A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease

NCT01482845

Alzheimer's Disease

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Delirium Anticholinergic Adverse Reaction Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

early onset deliryum on dementia

It was earlier than The median time of onset of delirium superimposed dementia

Anticholinergic burden

Intervention Type DRUG

The anticholinergic burden (ACB) was assessed using the Anticholinergic Burden Scale.

Higher ACB was described as equal or higher than 1.

Delirium on dementia (normal)

It was equal or later than The median time of onset of delirium superimposed dementia

Anticholinergic burden

Intervention Type DRUG

The anticholinergic burden (ACB) was assessed using the Anticholinergic Burden Scale.

Higher ACB was described as equal or higher than 1.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Anticholinergic burden

The anticholinergic burden (ACB) was assessed using the Anticholinergic Burden Scale.

Higher ACB was described as equal or higher than 1.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 65 years and older and diagnosis or fellow-up of Alzhemier dementia in outpatient clinic.

Exclusion Criteria

* The patients with a history of other than Alzhemier dementia or neurodegenerative disease (epilepsy, multiple sclerosis, Parkinson disease, etc.), terminal illness (malignancy, advanced organ failure) were excluded.

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No